Bio News
AbbVie said its bispecific antibody etentamig for multiple myeloma met the primary endpoint in a phase 3 clinical trial. Etentamig reduced the risk of disease progression or death by 60% compared with standard therapy, while its response rate was 74%, significantly higher than the 46% reported in the standard-therapy group. AbbVie said etentamig had a safety advantage over the competing drug, with cytokine release syndrome occurring in 28% of patients and ICANS reported in only 1 patient.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
